Latest Conference Coverage

Bruce Trapp, PhD: Insights Gleaned from Myelocortical Multiple Sclerosis

The chairman of the Department of Neuroscience at the Lerner Research Institute spoke about what the implications of the new subtype of MS could be in the understanding of the disease.

Carrie Hersh, DO, MSc: Assessing Real-World MS Data to Compare DMTs

The MS neurologist at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed how leveraging real-world datasets can help reduce indication bias when comparing treatments for multiple sclerosis.

MS Patients With Positive Prognostic Profiles Less Likely to Initiate Recommended DMTs

Patients with favorable prognostic profiles or relapsing-remitting MS are the least likely to initiate high-efficacy disease-modifying therapies recommended by their physician, with many patients citing access challenges.

Alissa Willis, MD: Identifying Patients With MS at Risk for Suicide

Despite high rates of depression in MS, picking up on signs that an individual may be at risk for suicide can be difficult. The staff neurologist at Cleveland Clinic’s Mellen Center discussed some of the red flags.

Fingolimod Provides Consistent Efficacy in Patients With MS Irrespective of Migraine

Results of a pooled analysis of 3 clinical trials suggest that the magnitude of fingolimod’s treatment effect in MS is not affected by the presence of migraine or headache in patients.

Carrie Hersh, DO, MSc: Shared Decision Making in Multiple Sclerosis

The MS neurologist at Cleveland Clinic’s Lou Ruvo Center for Brain Health spoke about the factors that should be taken into account when making treatment decisions in MS, such as tolerability, affordability, and the desire to start family planning.

Teriflunomide Shows Long-Term Efficacy in MS Across Age Groups

Data from 5 clinical trials and their extensions along with 1 real-world study suggest that treatment with teriflunomide can help patients of varying ages maintain low annualized relapse rates and stable EDSS scores.

Interim EVOLVE-MS-1 Data Support Efficacy, Tolerability of Diroximel Fumarate in Relapsing Multiple Sclerosis

Diroximel fumarate may be an effective treatment option in both newly diagnosed and interferon/glatiramer acetate switch patients. Interim results show it significantly reduced disease activity and was well tolerated, with low rates of gastrointestinal adverse effects leading to treatment discontinuation.

Emily Splichal, DPM: Insoles for Improving Balance, Posture, and Gait in MS

The podiatrist and CEO of Naboso Technology spoke about the potential of simple textured insoles to improve gait, posture, and balance in patients with MS experiencing ambulation issues.

Alemtuzumab Maintains Long-Term Efficacy in MS, Shows Superiority to Interferon Beta

Follow-up data extending out to 8 years suggest that both clinical and MRI outcomes are better with alemtuzumab (Lemtrada) than interferon beta-1a in patients with relapsing-remitting multiple sclerosis.

Amy Sullivan, PsyD: Personalized Approach to Fatigue in Multiple Sclerosis

The Director of Behavioral Medicine at the Mellen Center for MS Treatment and Research at the Cleveland Clinic spoke about how she approaches fatigue in MS from a behavioral standpoint.

Higher-Efficacy DMTs May Have Favorable Effect on Depression in MS

Given that depression is a common symptom in patients with MS and is associated with increased morbidity and mortality, the investigators examined the effects of lower-efficacy DMTs and higher-efficacy DMTs on depression.

MAGNIMS Score Can Predict MS Clinical Activity, Disease Progression

In those with MS treated with subcutaneous interferon beta-1a, Magnetic Resonance Imaging in multiple sclerosis scores may be predictive of the time to new clinical disease activity and disease progression.

Nonadherence to Disease-Modifying Treatment in MS Has Significant Clinical and Economic Effects

In order to better understand the clinical and economic impacts of nonadherence to disease-modifying therapy, the investigators conducted a cost-consequence analysis among patients taking once- or twice-daily DMTs.

Cognitive Behavioral Therapy More Effective Than Sleep Education for Insomnia in MS

The investigators sought to compare a 6-week, in-person intervention with CBT for insomnia and a brief education program in patients with MS who reported symptoms of insomnia.

Cladribine Reduces MRI Lesions Across Subgroups in ORACLE-MS Study

The subgroups were defined by baseline characteristics that are known to be potential modifiers of risk to conversion to clinically-definite multiple sclerosis, including age, gender, first classification of demyelinating event, presence of T1 Gd+ lesions, and number of active T2 lesions.

Stephen Silberstein, MD: Treating Medication Overuse Headache

The director of the Jefferson Headache Center at Jefferson University Hospital discussed the need for physicians to revisit how they treat patients with chronic migraine who have developed medication overuse headache.

The State of Charcot-Marie-Tooth Disease: An In-Depth Interview With K. Florian P. Thomas, MD

The Director of the Multiple Sclerosis and Hereditary Neuropathy Centers at Seton Hall-Hackensack Meridian School of Medicine shared insight into what clinicians should know about Charcot-Marie-Tooth disease.

Amit Rakhit, MD, MBA: Measuring Improvement in Fragile X Syndrome, Other Rare Conditions

The chief medical officer and head of Research & Development at Ovid Therapeutics spoke about what prompted the development of this scale to measure improvement for patients with Fragile X syndrome, and possibly other conditions.

Stroke History, Bleeding Risk Reduce Likelihood of Left Atrial Appendage Closure in AFib

Despite a 40-fold increase in the use of LAAC in a 9-year period, those who had a history of stroke with major bleeds and higher comorbidity were less likely to have LAAC.

Endovascular Acute Ischemic Stroke Treatment Shows Similar Success Rates Regardless of Prestroke Disability

Similar rates of successful clinical and procedural EVT outcomes were reported in patients with and without prestroke disability; however, prospective studies are needed to confirm this finding.

Patients With OSA and Concurrent AF Should Be Screened for Cerebral Microbleeds

The research fellow in the Department of Radiology at Mayo Clinic Jacksonville spoke about the reasoning for conducting this study and what the findings mean for physicians in clinical practice.

Rebecca Ichord, MD: Addressing Pediatric Stroke With Thrombectomy and Thrombolysis

The director of the Pediatric Stroke Program at CHOP discussed the findings of a single-center study exploring the incidence of children presenting with acute arterial ischemic stroke who may have been eligible for mechanical thrombectomy.

Rodolfo Savica, MD, PhD: Dyskinesias in Atypical Parkinsonism

The associate professor of neurology at Mayo Clinic spoke about the findings of a population-based cohort study seeking to investigate the incidence of levodopa-induced dyskinesia in atypical parkinsonism.

Rebecca Ichord, MD: Challenges in Providing Care for Pediatric Stroke

The director of the Pediatric Stroke Program at CHOP spoke about the need to improve early recognition and assessments in pediatric stroke, and how ultimately, awareness of the condition is a huge step toward achieving this goal.

Fingolimod Significantly Reduces Blood NfL in Relapsing-Remitting Multiple Sclerosis

NfL levels were reduced during treatment with fingolimod, providing further evidence of the long-term benefit of the drug and demonstrating a greater impact of highly effective therapy in relapsing-remitting multiple sclerosis.

Robert Fox, MD: Neurofilament Light and the SPRINT MS Trial

The staff neurologist at Cleveland Clinic shared his insight from the study, as well as what these data can do to further inform the use of this biomarker in progressive MS trials.

MSProDiscuss Tool Shows Signs of Validity for Clinical Use in Multiple Sclerosis

The lead investigator noted that “the study results are a promising step toward having a scientifically-validated tool for clinical use that can facilitate physician-patient conversations and ultimately help to get ahead of MS progression.”

Margaret Moline, PhD: Next-Morning Residual Effects of Lemborexant in Insomnia

The International Project Team Lead spoke about the results of study endpoints that assessed the potential for next-morning residual effects of lemborexant, which is in development for insomnia.

Evobrutinib Reduces Lesions in Patients With Relapsing MS

Evobrutinib is the first BTK inhibitor to demonstrate clinical proof of concept in multiple sclerosis, reducing Gd+ lesions in a 75-mg, once-daily dose.